Show simple item record

dc.contributor.authorNational Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group
dc.date.accessioned2018-04-04T13:21:50Z
dc.date.issued2018-05
dc.identifier.citationClinical oncology (Royal College of Radiologists (Great Britain)), 2018, 30 (5), pp. 280 - 284
dc.identifier.issn0936-6555
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1629
dc.identifier.eissn1433-2981
dc.identifier.doi10.1016/j.clon.2018.02.031
dc.description.abstractThe use of proton beam therapy (PBT) offers the opportunity to improve greater conformality of radiotherapy treatment delivery in some patients. However, it is associated with a high capital cost and the need to build new dedicated facilities. We discuss how the global radiotherapy community can respond to the challenge of producing high-quality evidence of clinical benefit from PBT in adult patients. In the UK, the National Cancer Research Institute-funded Clinical and Radiotherapy Translational group has established the PBT Clinical Trial Strategy Group. An eight-point framework is described that can assist the development and delivery of high-quality clinical trials.
dc.formatPrint-Electronic
dc.format.extent280 - 284
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectNational Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectResearch Design
dc.subjectAdult
dc.subjectClinical Trials as Topic
dc.subjectProton Therapy
dc.subjectUnited Kingdom
dc.titleProton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit.
dc.typeJournal Article
dcterms.dateAccepted2018-02-19
rioxxterms.versionofrecord10.1016/j.clon.2018.02.031
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfClinical oncology (Royal College of Radiologists (Great Britain))
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team
pubs.publication-statusPublished
pubs.volume30
pubs.embargo.termsNot known
icr.researchteamICR-CTSU Urology and Head and Neck Trials Teamen_US
dc.contributor.icrauthorHall, Emmaen


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record